Crane NXT (CXT) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
7 May, 2026Executive summary
Achieved 17% year-over-year sales growth to $388 million, with 6% organic growth, driven by strong SAT performance and the early completion of the Antares Vision acquisition, expanding into life sciences and food & beverage markets.
Adjusted EBITDA margin expanded by 80 basis points to 19.3%, with adjusted EPS of $0.60, while GAAP EPS was $0.11 due to higher acquisition-related costs and stock-based compensation.
Operating profit declined 40.5% to $22.2 million, and net income attributable to common shareholders was $6.4 million, reflecting acquisition and integration costs.
Integration of De La Rue and Antares Vision contributed to segment realignment and growth, with restructuring charges incurred.
On track to meet full-year expectations, with normal seasonality anticipated.
Financial highlights
Q1 sales reached $388 million, up from $330.3 million year-over-year; net sales rose 17.4%.
Adjusted EBITDA was $74.7 million (19.3% margin), up from $61 million (18.5%) year-over-year.
Adjusted EPS was $0.60, while diluted GAAP EPS was $0.11.
Free cash flow was $(24.1) million, with adjusted free cash flow at $(18.9) million and conversion at 19%.
Net income margin was 1.7%; operating margin decreased to 5.7% from 11.3% year-over-year.
Outlook and guidance
Full-year 2026 sales growth guidance raised to 15%-17%, reflecting the Antares Vision acquisition.
Adjusted EPS guidance maintained at $4.10-$4.40.
Adjusted EBITDA margin expected at ~24%-27% for the year.
Free cash flow conversion targeted at 90%-110% for the year.
88% of remaining performance obligations expected to be recognized as revenue in 2026.
Latest events from Crane NXT
- Targets ~$2.5B revenue and $600M EBITDA by 2028 through growth, M&A, and innovation.CXT
Investor Day 202617 Apr 2026 - Board recommends electing nine directors, auditor ratification, and approving executive pay.CXT
Proxy filing7 Apr 2026 - Votes are sought for director elections, auditor ratification, and executive pay approval.CXT
Proxy filing7 Apr 2026 - Sales up 11.4%, Adjusted EPS $4.06, 2026 guidance strong, dividend up 6%.CXT
Q4 202512 Feb 2026 - Q3 2025 sales up 10% to $445.1M, SAT growth, and Antares Vision acquisition announced.CXT
Q3 20253 Feb 2026 - Q2 sales rose 9.1% to $404.4M, with strong SAT growth and robust free cash flow conversion.CXT
Q2 20253 Feb 2026 - Q1 2025 sales up 5.3% to $330.3M; full-year sales growth guidance raised to 6–8%.CXT
Q1 20253 Feb 2026 - Q3 2024 sales up 14.3% to $403.5M, with strong M&A and lower margins year-over-year.CXT
Q3 20243 Feb 2026 - Acquisition-driven growth, tech innovation, and strong cash flow support margin expansion and deleveraging.CXT
24th Annual Diversified Industrials & Services Conference3 Feb 2026